Operations Data Challenges Limit the Value Realized from Pharma 4.0
Pharmaceutical and biotech portfolios continue to transition from high volume blockbusters to a diversified set of lower volume, targeted therapeutics. At the same time, many companies are pursuing localized manufacturing to adjust to supply chain challenges and to improve access to medicine. The industry must also address increased pricing pressure due to inflation and government policies. Successfully managing a broad portfolio, expanding global access, and maintaining margins requires greater manufacturing agility while adhering to industry regulations.